Target intelligence / Profile preview

PLCG1 antisense RNA 1 (PLCG1-AS1)

Target
PLCG1-AS1
Molecular classification
Other (long noncoding RNA, lncRNA)
01

Overview

PLCG1 antisense RNA 1 (PLCG1-AS1) is a long noncoding RNA transcribed from the antisense strand at the PLCG1 gene locus. It does not code for a protein and is distinct from the well-characterized protein enzyme Phospholipase C gamma 1 (PLCG1). There is minimal experimental data or functional annotation for PLCG1-AS1 in the biomedical literature. Its aliases (e.g., TOP1-AS1) may create confusion, but PLCG1-AS1 should not be equated with the protein-coding PLCG1 gene, a critical enzyme in signal transduction and cancer. At present, PLCG1-AS1 is not a recognized therapeutic target, nor are there known drugs or biomarkers associated with it. Notes on nomenclature: - The canonical abbreviation and full name should follow: PLCG1 antisense RNA 1 (PLCG1-AS1). - Commonly encountered aliases (such as TOP1-AS1) often conflate this lncRNA with unrelated entities, further emphasizing the need for careful distinction in structured data records. - Several database entries (e.g., NCBI Gene, Ensembl) confirm the classification of PLCG1-AS1 as a long noncoding RNA, not a protein-coding gene, enzyme, or receptor. If a conventional drug discovery or pharmacological target is required, users should refer to the protein Phospholipase C gamma 1 (PLCG1), not PLCG1-AS1. If interested in the general regulatory or biomarker role of noncoding RNAs, PLCG1-AS1 may be a candidate for future research, but it currently lacks robust functional annotation.

Other names
TOP1-AS1PLCG1-AS1
02

Mechanism of action

Not applicable; no drugs targeting PLCG1-AS1 directly are known

03

Biological functions

Gene regulation (antisense lncRNAs often regulate transcription of neighboring or overlapping genes)Possible epigenetic regulation (common for lncRNAs)No established specific functions for PLCG1-AS1 due to lack of experimental characterization
04

Disease associations

Other (No well-established connection to major human diseases is currently documented for PLCG1-AS1 in primary scientific references; possible generic cancer or regulatory implications, but evidence is limited)

Beyond the preview

Go deeper on PLCG1 antisense RNA 1 (PLCG1-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLCG1 antisense RNA 1 (PLCG1-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call